Avadel Pharmaceuticals sees a surge of institutional buying, with 14 funds reporting stakes in a volatile specialty‑drug stock that’s still loss‑making but near a 52‑week high. Read why big players may signal a turning point for this $1.84 billion c…

Avadel Pharmaceuticals, a specialty pharmaceutical company, is facing significant financial challenges, including a negative price-to-earnings ratio and stock price volatility, which raises concerns about its financial stability and investor confide…

Avadel Pharmaceuticals faces a tumultuous period, balancing a recent legal victory with a boardroom battle and investor concerns over governance and financial stability.

Avadel Pharmaceuticals PLC is a specialty pharmaceutical company that has carved a niche in the healthcare industry by focusing on innovative treatments for chronic urological, central nervous system, and sleep disorders.

Avadel Pharmaceuticals’ stock price surged after a court victory allowed the company to expand trials for its medication LUMRYZ, treating Idiopathic Hypersomnia and narcolepsy.

Avadel Pharmaceuticals PLC’s stock surged after a court victory allowed the company to expand trials for its drug LUMRYZ, boosting its growth prospects and revenue potential.

Avadel Pharmaceuticals PLC, a specialty pharmaceutical company, faces financial challenges but remains a key player in the industry with a promising pipeline of innovative therapies for chronic disorders.